Key Points
- EVP Francisco Fraga sold 650 McKesson shares at an average of $1,102.96, worth about $716,924, under a pre-arranged Rule 10b5-1 plan. He retained 4,414 shares after the sale.
- McKesson reported quarterly EPS of $11.68, beating the $10.72 consensus, and revenue of $110.96 billion, up 7.5% year over year.
- The company declared a quarterly dividend of $0.94 per share, equivalent to $3.76 annually and a 0.4% yield.
McKesson Corporation (NYSE:MCK - Get Free Report) EVP Francisco Fraga sold 650 shares of the firm's stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $1,102.96, for a total value of $716,924.00. Following the completion of the sale, the executive vice president owned 4,414 shares in the company, valued at approximately $4,868,465.44. This represents a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Francisco Fraga also recently made the following trade(s):
- On Wednesday, November 4th, Francisco Fraga sold 600 shares of McKesson stock. The stock was sold at an average price of $1,050.00, for a total transaction of $630,000.00.
- On Thursday, October 15th, Francisco Fraga sold 800 shares of McKesson stock. The stock was sold at an average price of $995.80, for a total value of $796,640.00.
McKesson Trading Down 1.0%
McKesson stock opened at $1,060.79 on Friday. The firm has a market capitalization of $123.68 billion, a P/E ratio of 27.28, a PEG ratio of 1.99 and a beta of 0.27. McKesson Corporation has a 52 week low of $723.68 and a 52 week high of $1,121.50. The stock has a fifty day moving average price of $938.13 and a 200 day moving average price of $868.12.
McKesson (NYSE:MCK - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $11.68 EPS for the quarter, beating analysts' consensus estimates of $10.72 by $0.96. McKesson had a negative return on equity of 253.21% and a net margin of 1.12%. The company had revenue of $110.96 billion during the quarter, compared to the consensus estimate of $109.90 billion. During the same period in the previous year, the firm posted $9.86 earnings per share. McKesson's quarterly revenue was up 7.5% compared to the same quarter last year. As a group, equities analysts predict that McKesson Corporation will post 45.26 EPS for the current year.
McKesson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, January 4th. Shareholders of record on Tuesday, December 1st will be issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Tuesday, December 1st. McKesson's dividend payout ratio is 9.67%.
Hedge Funds Weigh In On McKesson
Large investors have recently bought and sold shares of the business. Nvwm LLC grew its position in McKesson by 933.3% in the third quarter. Nvwm LLC now owns 31 shares of the company's stock worth $26,000 after acquiring an additional 28 shares during the period. Delos Wealth Advisors LLC purchased a new stake in shares of McKesson in the second quarter valued at about $27,000. Trellis Wealth Advisors LLC acquired a new position in shares of McKesson during the 3rd quarter worth $32,000. GK Wealth Management LLC purchased a new position in shares of McKesson in the third quarter valued at $38,000. Finally, Curry Webb Wealth Management LLC acquired a new stake in shares of McKesson during the third quarter valued at $38,000. Institutional investors and hedge funds own 85.07% of the company's stock.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on the company. Argus lifted their target price on McKesson from $850.00 to $970.00 and gave the company a "buy" rating in a research note on Thursday, September 3rd. Royal Bank Of Canada lifted their price objective on McKesson from $845.00 to $965.00 and gave the stock a "sector perform" rating in a research note on Thursday. TD Cowen upped their price objective on McKesson from $1,006.00 to $1,200.00 and gave the company a "buy" rating in a research note on Thursday. Robert W. Baird set a $1,015.00 price objective on McKesson in a report on Thursday, August 6th. Finally, Citigroup raised their price target on McKesson from $945.00 to $1,000.00 and gave the company a "buy" rating in a report on Friday, July 24th. Fifteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,026.18.
Check Out Our Latest Stock Report on MCK
Key Headlines Impacting McKesson
Here are the key news stories impacting McKesson this week:
- Positive Sentiment: McKesson beat fiscal Q2 2027 estimates, reporting adjusted EPS of $11.68 and revenue of about $111 billion, up roughly 7.5% year over year. The company also raised its fiscal 2027 adjusted EPS outlook to $45.60–$46.40, supported by specialty-drug demand, higher prescription volumes and operating gains. MCK Q2 Earnings Beat Estimates on Specialty Growth, Outlook Raised
- Positive Sentiment: Analyst sentiment has strengthened: UBS raised its price target to $1,250 and maintained a Buy rating, while TD Cowen and Leerink Partners lifted targets to $1,200. Separately, Zacks upgraded MCK to Rank #2 (Buy), citing improving earnings prospects. Zacks upgrades McKesson to Buy
- Neutral Sentiment: EVP Francisco Fraga sold 650 shares under a pre-arranged Rule 10b5-1 plan and retained 4,414 shares. The filing does not explain the purpose of this latest sale; an earlier sale was described as covering tax withholding on vested equity awards. SEC filing
- Negative Sentiment: RBC raised its price target but kept a Sector Perform rating and set a $965 target, below the recent share price. That more cautious view may temper enthusiasm after MCK’s strong run. RBC comments on McKesson’s execution
About McKesson
(
Get Free Report)
McKesson Corporation is a healthcare services and information technology company that distributes pharmaceuticals and other medical products. Its customers include pharmacies, hospitals, health systems, clinics and other healthcare providers.
The company also provides medical-surgical supplies and technology and services that support pharmacy operations, prescription management and care delivery. Its offerings include specialized support for oncology and other areas of care.
Founded in 1833, McKesson serves customers primarily in the United States and Canada.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
